A Q&A With A Biotech Founder/Entrepreneur

By Dan Schell, Chief Editor, Clinical Leader

While an Entrepreneur in Residence at Atlas Venture, Nello Mainolfi, Ph.D., helped cofound Kymera Therapeutics, a Boston-based clinical-stage biopharmaceutical company focused on targeted protein degradation, a new approach to addressing previously intractable disease targets. Prior to Atlas, he used his training as a chemist to work seven years at the Novartis Institutes for Biomedical Research, where he helped identify more than 10 compounds that have entered preclinical and clinical development.